Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 3
Submit an article Journal homepage
220
Views
2
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Elucidating the structure and cytochrome P450-mediated mechanism for novel metabolites of GDC-0575 in rats

Chenghong Zhanga Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA;b Drug Metabolism and Pharmacokinetics, Global Blood Therapeutics, South San Francisco, CA, USA
,
Sungjoon Choa Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USACorrespondence[email protected]
,
José G. Napolitanoc Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, USA
,
David Russellc Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, USA
,
Christine Guc Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, USA;d Oncology Discovery, AbbVie, Inc., South San Francisco, CA, USA
,
Alan Deesec Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, USA;e Currently retired
,
Chong Hanc Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, USA
,
Yuan Chena Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA
&
Shuguang Maa Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA;f Pharmacokinetics and Drug Metabolism, Amgen, Inc., South San Francisco, CA, USA
 show all
Pages 219-228 | Received 25 Feb 2022, Accepted 03 Apr 2022, Published online: 21 Apr 2022

References

  • Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, Rosenberg S, Fesik S, Zhang H. 2003. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther. 2(6):543–548.
  • Davis JA, Greene RJ, Han S, Rock DA, Wienkers LC. 2011. Formation of raloxifene homo-dimer in CYP3A4, evidence for multi-substrate binding in a single catalytically competent P450 active site. Arch Biochem Biophys. 513(2):110–118.
  • Di Marco A, Yao D, Laufer R. 2003. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur J Biochem. 270(18):3768–3777.
  • Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, Smythe C. 2001. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol. 154(5):913–923.
  • Gillam EM, Notley LM, Cai H, De Voss JJ, Guengerich FP. 2000. Oxidation of indole by cytochrome P450 enzymes. Biochemistry. 39(45):13817–13824.
  • Grobe N, Kutchan TM, Zenk MH. 2012. Rat CYP2D2, not 2D1, is functionally conserved with human CYP2D6 in endogenous morphine formation. FEBS Lett. 586(13):1749–1753.
  • Gu C, Artelsmair M, Elmore CS, Lewis RJ, Davis P, Hall JE, Dembofsky BT, Christoph G, Smith MA, Chapdelaine M, et al. 2018. Late-occurring and long-circulating metabolites of GABAAα2,3 receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance. Drug Metab Dispos. 46(3):303–315.
  • Han C, Green K, Oehring K, Meili A, Pfeifer E, Scalone M, Gosselin F. 2018. An efficient through-process for Chk1 kinase inhibitor GDC-0575. Org Process Res Dev. 22(3):344–350.
  • Hiroi T, Chow T, Imaoka S, Funae Y. 2002. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos. 30(9):970–976.
  • Hiroi T, Imaoka S, Chow T, Funae Y. 1998. Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta. 1380(3):305–312.
  • Hop CE, Wang Z, Chen Q, Kwei G. 1998. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 87(7):901–903.
  • Kato R, Yamazoe Y. 1992. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol Lett. 64-65 Spec No:661–667.
  • Kobayashi K, Urashima K, Shimada N, Chiba K. 2002. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol. 63(5):889–896.
  • Lord CJ, Garrett MD, Ashworth A. 2006. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res. 12(15):4463–4468.
  • Mikus G, Somogyi AA, Bochner F, Eichelbaum M. 1991a. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol. 41(5):757–762.
  • Mikus G, Somogyi AA, Bochner F, Eichelbaum M. 1991b. Thebaine O-demethylation to oripavine: genetic differences between two rat strains. Xenobiotica. 21(11):1501–1509.
  • Stark GR, Taylor WR. 2006. Control of the G2/M transition. Mol Biotechnol. 32(3):227–248.
  • Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J. 2005. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 25(9):3553–3562.
  • Takahashi RH, Grandner JM, Bobba S, Liu Y, Beroza P, Zhang D, Ma S. 2020. Novel homodimer metabolites of GDC-0994 via cytochrome P450-catalyzed radical coupling. Drug Metab Dispos. 48(6):521–527.
  • Takahashi RH, Ma S, Robinson SJ, Yue Q, Choo EF, Khojasteh SC. 2015. Elucidating the mechanisms of formation for two unusual cytochrome P450-mediated fused ring metabolites of GDC-0623, a MAPK/ERK kinase inhibitor. Drug Metab Dispos. 43(12):1929–1933.
  • Tse AN, Carvajal R, Schwartz GK. 2007. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res. 13(7):1955–1960.
  • Turan VK, Mishin VM, Thomas PE. 2001. Clotrimazole is a selective and potent inhibitor of rat cytochrome P450 3A subfamily-related testosterone metabolism. Drug Metab Dispos. 29:837–842.
  • Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. 2009. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 41(4):573–643.
  • Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H. 2003. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem. 278(24):21767–21773.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.